about
Partial V(D)J recombination activity leads to Omenn syndromeStructural and functional basis for JAK3-deficient severe combined immunodeficiencyMIF/CD74 axis is a target for novel therapies in colon carcinomatosis.Phase II study on lapatinib in advanced EGFR-positive chordoma.Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumoursOmenn syndrome: a disorder of Rag1 and Rag2 genes.Mutations in conserved regions of the predicted RAG2 kelch repeats block initiation of V(D)J recombination and result in primary immunodeficienciesProteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy.Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma.Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma.N-terminal RAG1 frameshift mutations in Omenn's syndrome: internal methionine usage leads to partial V(D)J recombination activity and reveals a fundamental role in vivo for the N-terminal domains.Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haemopoietic stem cell transplantation to consolidate primary treatment.Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework.The ZNF75 zinc finger gene subfamily: isolation and mapping of the four members in humans and great apes.High CD133 expression levels in gastrointestinal stromal tumors.Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation.Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma.New transcriptional-based insights into the pathogenesis of desmoplastic small round cell tumors (DSRCTs)Functional mapping of receptor tyrosine kinases in myxoid liposarcoma.Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).Peripheral blood stem cell collection in pediatric patients: feasibility of leukapheresis under anesthesia in uncompliant small children with solid tumors.V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentationsIn vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.Evidence for activation of KIT, PDGFRα, and PDGFRβ receptors in the Ewing sarcoma family of tumorsThe CD133 expression levels and its role as potential cancer stem cells marker in gastrointestinal stromal tumorAntiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1The RAG1/RAG2 complex constitutes a 3' flap endonuclease: implications for junctional diversity in V(D)J and transpositional recombinationPrenatal diagnosis of RAG-deficient Omenn syndrome
P50
Q24336454-C08A1884-FF94-4AF0-A00A-AE7C58400747Q28253330-03258B6D-CDF9-47CE-9460-7543A89D0F29Q30836134-B04818F8-17D3-47C5-BE13-ADA3D26FAD2EQ33274760-7E8E6F17-9AD3-4345-9B00-00826AE35C22Q33275064-863281B0-F106-4C9C-A766-9DCDD754D8D7Q33433105-5EFB85FA-5EB5-4E3A-B861-528719CDBFFCQ33607425-03DF0FBC-DFA8-466C-A307-3ECBAC0729C4Q33964869-209247CD-4C72-4274-ACD8-E62DAAFA4F52Q34029127-A648D23A-5D21-4403-8942-CE8577A268AEQ34633416-77450C87-DC5C-4E0A-869C-B03AD5E89741Q35799863-441662C3-C765-431E-99A2-BB73483D3944Q35850311-80D83914-6DAF-49F5-B4D4-38827CE91BE2Q36272148-6AD62ABB-3CFC-4C9C-B69D-C48F5A3B5036Q36615949-F6C38C1A-CD4C-472D-B04A-5193B8DCA82DQ37688972-7ED3D845-E572-468A-A9ED-94F6355CF649Q38355396-987F1534-E228-4584-85DC-05BA6592D42CQ39564970-45DE892B-7132-4057-8F96-EBCAA2843993Q39805159-6F7EA754-66BB-427B-B1AA-6116A340885AQ39960404-4D418B15-98B5-44DD-B9A3-CF1BAD19BFB1Q40523486-F1308D9A-4BBB-48E1-841E-6DF0B78C8BCCQ41986236-E7E1BD5B-4310-41A0-A984-E6A95B269032Q43045056-CBE987B2-6789-4376-B4F2-E0CE80EE0CBAQ45345506-38C26B14-816B-4F90-9056-2BE44F8B0894Q46273752-A12CAD87-29BD-4853-B441-D923F301F65AQ51217530-1959FE37-F513-4113-9B36-04336E63CC50Q57173925-BCDF642E-732B-4B83-A39F-7B80064D147CQ58813285-EFF09066-F6FF-4517-B62F-3489FF985880Q58813348-1FD83D0A-36FC-4EEA-94BE-73E10C0AD705Q59217176-68D5611E-25EC-4F00-B70A-6B4A7289C75FQ60048095-53FF507F-242B-4F92-AB2F-D2E58C353D8CQ73353796-C4ED903A-AD4E-4548-910E-2BEF8F1797B6Q73508909-4D31D49D-7A3D-476D-BF3B-31B7F573337A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fabio Bozzi
@ast
Fabio Bozzi
@en
Fabio Bozzi
@es
Fabio Bozzi
@nl
Fabio Bozzi
@sl
type
label
Fabio Bozzi
@ast
Fabio Bozzi
@en
Fabio Bozzi
@es
Fabio Bozzi
@nl
Fabio Bozzi
@sl
prefLabel
Fabio Bozzi
@ast
Fabio Bozzi
@en
Fabio Bozzi
@es
Fabio Bozzi
@nl
Fabio Bozzi
@sl
P1053
H-6091-2017
P106
P1153
6602399904
P21
P31
P3829
P496
0000-0003-0729-1288